Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

Meinolf Karthaus(Evangelisches Krankenhaus Bielefeld), Lena Weiss(LMU Klinikum), Manfred Welslau(Praxis für Hämatologie und Onkologie), Henning Pelz(Praxis für Hämatologie und Onkologie), Volker Heinemann(LMU Klinikum), Jorge Riera‐Knorrenschild, Timo Reisländer(Servier (Germany)), Thomas J. Ettrich(Universität Ulm), Ulrich Kaiser(University of Applied Sciences Landshut), Linde Kehmann(Charité - Universitätsmedizin Berlin), Jürgen Hess(Servier (Germany)), Albrecht Kretzschmar(Roche (Switzerland)), Swantje Held(AIO Studien gGmbH)

BMC Cancer

July 23, 2024

10.1186/s12885-024-12599-7

Cited by 3

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2014|1.7k

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

|JAMA Oncology|2016|722

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

|European Journal of Cancer|2011|615